Human Milk Oligosaccharides (HMO) Market Size Worth $1,799.96 Million By 2032 | CAGR: 22.8%

Human Milk Oligosaccharides (HMO) Market Size Worth $1,799.96 Million By 2032 | CAGR: 22.8%


The global human milk oligosaccharides (HMO) market size is expected to reach USD 1,799.96 million by 2032, according to a new study by Polaris Market Research. The report “Human Milk Oligosaccharides (HMO) Market Share, Size, Trends, Industry Analysis Report, By Type (2’FL, 3’FL, 3’SL, 6’SL); By Application; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth. 

Human Milk Oligosaccharides (HMOs) are complex carbohydrates or sugars naturally found in human breast milk. HMOs are unique to human milk and are not present in significant amounts in other mammalian milk, including cow's milk.

HMOs serve as a source of infant nutrition, although the baby does not directly digest them. Instead, they act as prebiotics, which means they serve as food for beneficial bacteria in the infant's gut. The gut microbiota is crucial in immune system development, digestion, and overall health. HMOs selectively promote the growth of specific beneficial bacteria, such as Bifidobacteria, while inhibiting the growth of harmful pathogens.

Human Milk Oligosaccharides (HMOs) are essential constituents of human breast milk and are available in various concentrations and compositions. The unique nature of HMOs requires specific regulatory approvals for their use. In the United States, oligosaccharides are authorized to be incorporated into food products rather than categorized as dietary supplements and are subject to the Generally Recognized as Safe (GRAS) regulations.

For instance, the GRAS-approved HMO product line is CARE4U, developed by DuPont, which is utilized in infant formula and toddler foods. This approval ensures its safety for consumption. Furthermore, the growing demand for HMOs has led to a novel food safety assessment to seek support from the European Commission for their usage.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/human-milk-oligosaccharides-hmo-market/request-for-sample

The global adoption of Human Milk Oligosaccharides (HMOs) has increased. According to a World Economic Forum article published in January 2022, the number of births in Japan decreased by 2.8% in 2020 compared to the previous year, reaching its lowest point since 1899.

The increasing demand for HMOs can be attributed to lifestyle improvements and a growing focus on health and wellness. HMOs are utilized in functional food and beverage products and food supplements to address disorders and mitigate high-risk health conditions. This factor has significantly contributed to the growth of the global HMO industry. However, the high costs associated with HMO products are expected to pose a major challenge to market growth during the forecast period.

The COVID-19 pandemic has had a significant impact on the HMO industry. During the initial phase of the pandemic, there was a surge in demand for HMOs as consumers engaged in panic buying for at-home consumption. It resulted in increased sales of HMOs, considered immune-boosting products.

Human Milk Oligosaccharides (HMO) Market Report Highlights

  • In 2022, the infant formula segment accounted for the largest market share due to the increasing demand for HMOs in infant formula design. HMOs offer beneficial properties like prebiotic effects, infection prevention, memory enhancement, gut health maintenance, and brain development. These factors drive the demand for HMOs in infant formulas.
  • In 2022, the drug store or pharmacy segment held the highest market share in the Human Milk Oligosaccharides market and is projected to continue growing. It is primarily due to the segment's focus on attracting and retaining customers amidst rising competition from mail-order retailers and supercenters.
  • The Asia Pacific region expected to witness significant growth in the Human Milk Oligosaccharides (HMO) market due to growing awareness of the benefits of HMOs in infant nutrition and overall health in the region. As consumers become more health-conscious and seek high-quality nutrition options for their infants, the demand for HMOs is expected to rise.
  • The global Human Milk Oligosaccharides industry players with a global presence including Elicityl S.A., Abbott Laboratories, Biosynth Carbosynth, Dextra Laboratories Ltd., Dupont Nutrition & Biosciences, Glycosyn, BASF S.E., Glycom A/S, Nestle Health Science, Neolacta Lifesciences Pvt. Ltd, Royal DSM, Medolac Laboratories, Chr. Hansen Holding A/S, ZuChem, Inbiose NV, and Royal FrieslandCampina N.V.

Polaris Market Research has segmented the human milk oligosaccharides (HMO) market report based on type, application, distribution channel, and region:

Human Milk Oligosaccharides (HMO), Type Outlook (Revenue - USD Million, 2019 - 2032)

  • 2’FL
  • 3’FL
  • 3’SL
  • 6’SL

Human Milk Oligosaccharides (HMO), Application Outlook (Revenue - USD Million, 2019 - 2032)

  • Infant Formula
  • Functional Food & Beverage
  • Food Supplements

Human Milk Oligosaccharides (HMO), Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)

  • Hypermarkets & Supermarkets
  • Drug Store or Pharmacy
  • Online Sales Channel
  • Others

Fogless Mirror, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Human Milk Oligosaccharides (HMO) Market Report Scope

Report Attributes

Details

Market size value in 2024

USD 347.29 million

Revenue forecast in 2032

USD 1,799.96 million

CAGR

22.8% from 2024 – 2032

Base year

2023

Historical data

2019 – 2022

Forecast period

2024 – 2032

Quantitative units

Revenue in USD million and CAGR from 2024 to 2032

Segments Covered

By Type, By Application, By Distribution Channel, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa

Key Companies

Elicityl S.A., Abbott Laboratories, Biosynth Carbosynth, Dextra Laboratories Ltd., Dupont Nutrition & Biosciences, Glycosyn, BASF S.E., Glycom A/S, Nestle Health Science, Neolacta Lifesciences Pvt. Ltd, Royal DSM, Medolac Laboratories, Chr. Hansen Holding A/S, ZuChem, Inbiose NV, and Royal FrieslandCampina N.V.

For Specific Research Requirements

Request for Customized Report